Faculty Opinions recommendation of The role of public-sector research in the discovery of drugs and vaccines.

Author(s):  
Amy Barrios
Author(s):  
Ashley J. Stevens ◽  
David E. Benson ◽  
Jonathan J. Jensen ◽  
Sara E. Dodson ◽  
Mark L. Rohrbaugh

2011 ◽  
Vol 364 (6) ◽  
pp. 535-541 ◽  
Author(s):  
Ashley J. Stevens ◽  
Jonathan J. Jensen ◽  
Katrine Wyller ◽  
Patrick C. Kilgore ◽  
Sabarni Chatterjee ◽  
...  

2016 ◽  
Vol 7 (1) ◽  
pp. 35
Author(s):  
Irina Romodina ◽  
Maxim Silin

The paper is about sustainable public procurement as a new global trend in the development of a sustainable economy. The main question raised is the following: how could sustainable public procurement be implemented in Russia? We aim to answer the question by presenting the findings of survey, covering public procurement practices of 51 contracting authorities and documentation analysis of 400 public tenders, and investigating Russian legislation. The conducted survey aims to identify the aspects of sustainable public procurement already used by public authorities in procuring practices in Russia. The analysis of Russian legislation allows to define in which sections of procurement documentation different aspects of sustainability could be included. This paper provides a unique survey of sustainable procurement practices across the Russian public sector. Research also shows the prerequisites of implementation of sustainable public procurement in Russia.


BMJ ◽  
2019 ◽  
pp. l5766 ◽  
Author(s):  
Rahul K Nayak ◽  
Jerry Avorn ◽  
Aaron S Kesselheim

Abstract Objective To determine the extent to which late stage development of new drugs relies on support from public funding. Design Cohort study. Setting All new drugs containing one or more new molecular entities approved by the US Food and Drug Administration (FDA) between January 2008 and December 2017 via the new drug application pathway. Main outcome measures Patents or drug development histories documenting late stage research contributions by a public sector research institution or a spin-off company, as well as each drug’s regulatory approval pathway and first-in-class designation. Results Over the 10 year study period, the FDA approved 248 drugs containing one or more new molecular entities. Of these drugs, 48 (19%) had origins in publicly supported research and development and 14 (6%) originated in companies spun off from a publicly supported research program. Drugs in these groups were more likely to receive expedited FDA approval (68% v 47%, P=0.005) or be designated first in class (45% v 26%, P=0.007), indicating therapeutic importance. Conclusions A review of the patents associated with new drugs approved over the past decade indicates that publicly supported research had a major role in the late stage development of at least one in four new drugs, either through direct funding of late stage research or through spin-off companies created from public sector research institutions. These findings could have implications for policy makers in determining fair prices and revenue flows for these products.


Sign in / Sign up

Export Citation Format

Share Document